You are here

  • Home
  • Archive
  • Volume 17, Issue 1
  • The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors

https://doi.org/10.1136/ebm.2011.100103

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests LJA is a consultant, speaker and advisor and receives research support from Abbott, Amylin, Arena, BMIQ, GI Dynamics, GSK, Novo Nordisk, Orexigen, Vivus. CMA has participated on the advisory boards of Allergan, Amylin, Orexigin, Merck, Johnson & Johnson, Arena and Sanofi-Aventis, and has received research funding from Lilly, Amylin, Pfizer, Sanofi-Aventis, Orexigen, MetaProteomics and the Dr Robert C and Veronica Atkins Foundation.